Radioimmunodetection of malignant solid tumours.
An increased clinical utility of radiolabelled monoclonal antibodies (MoAb), recognizing a variety of different antigens expressed preferentially in malignant tissue, for localizing primary, metastatic and recurrent cancer has been documented in many recent investigations. This review focuses on both basic and practical aspects of radioimmunodetection in oncology and is a status report on the performance and limitations of radiolabelled antibody procedures currently applied to the clinical detection of malignant solid tumours. At this time clinically validated radioimmunodetection methods are available for colorectal, ovarian, breast, lung, thyroid medullary, and head and neck carcinoma, and melanoma. Recent advances in humanization of MoAb significantly improve the prospects of effective antibody-guided radiotherapy in the near future.
Kairemo
K J
KJ
Department of Clinical Chemistry, University of Helsinki, Finland.
Liewendahl
K
K
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis; D000911:Antibodies, Monoclonal / Q000276:immunology; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D051379:Mice; D009369:Neoplasms / Q000000981:diagnostic imaging*; D016719:Radioimmunodetection
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal